Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis

This systematic review and meta-analysis study investigates the predictive and prognostic value of PIK3CA mutations for HER2-positive breast cancer treated with tyrosine kinase inhibitors (TKIs). A search of the Medline, Embase, and Cochrane Library databases yielded 17 eligible studies (1706 patien...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biochimica et biophysica acta. Reviews on cancer 2023-01, Vol.1878 (1), p.188847-188847, Article 188847
Hauptverfasser:	Shi, Qiyun, Xuhong, Juncheng, Tian, Hao, Qu, Man, Zhang, Yi, Jiang, Jun, Qi, Xiaowei
Format:	Artikel
Sprache:	eng
Schlagworte:	Breast Neoplasms - drug therapy Breast Neoplasms - genetics Class I Phosphatidylinositol 3-Kinases - genetics Female HER2-positive breast cancer Humans Neoadjuvant Therapy PIK3CA mutations Prognosis Receptor, ErbB-2 - genetics Trastuzumab Tyrosine Kinase Inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This systematic review and meta-analysis study investigates the predictive and prognostic value of PIK3CA mutations for HER2-positive breast cancer treated with tyrosine kinase inhibitors (TKIs). A search of the Medline, Embase, and Cochrane Library databases yielded 17 eligible studies (1706 patients). In 10 neoadjuvant studies, the pathological complete response rate was significantly higher in wild-type PIK3CA (WT) patients than in mutated PIK3CA (MT) patients (OR = 0.45; 95% CI = 0.31–0.65; P
ISSN:	0304-419X 1879-2561
DOI:	10.1016/j.bbcan.2022.188847